IMMX 1.70 Immix Biopharma, Inc.
| Range: | 1.26-7.75 | Vol Avg: | 140173 | Last Div: | 0 | Changes: | 0.03 |
| Beta: | 0.12 | Cap: | 0.05B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Dec 16 2021 | Empoloyees: | 14 | ||
| CUSIP: | 45258H106 | CIK: | 0001873835 | ISIN: | US45258H1068 | Country: | US |
| CEO: | Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D. | Website: | https://www.immixbio.com | ||||
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
Stock Details
IMMX 7
Immix Biopharma initiated with a Buy at H.C. Wainwright
Robert Burns·Mon Jul 01 2024
H.C. Wainwright
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow